awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q26745614-1789222F-852F-4EB8-9469-16634F052863
Q26745614-1789222F-852F-4EB8-9469-16634F052863
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26745614-1789222F-852F-4EB8-9469-16634F052863
New treatment option for ovarian cancer: PARP inhibitors
P2860
Q26745614-1789222F-852F-4EB8-9469-16634F052863
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26745614-1789222F-852F-4EB8-9469-16634F052863
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
7e9de70282c938c75920e5473672a2a74be48ba6
P2860
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study